findmyKOL
Clinical trialNCT05128773TerminatedPhase 3Interventional

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

SponsorSanofiEnrollment3Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David Cameron, Professor of Oncology

    University of Edinburgh Cancer Centre, institute of Genetics and Cancer, Western General Hospital, Crewe Road South, EDINBURGH EH4 2XU Scotland

    Study Chair
  • Etienne Brain, MD PhD

    Institut Curie (Saint-Cloud and Paris), 35 rue Dailly, 92210 Saint-Cloud

    Study Chair
  • Otto Metzger, MD

    Dana-Farber Cancer Institute, 450 Brookline Avenue Yawkey 1250

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Chile
  • Investigational Site Number :1521622

    Santiago, Reg Metropolitana de Santiago, Chile

China
  • Investigational Site Number :1561599

    Haikou, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Feb 2022
Primary completion
13 Oct 2022
Completion
13 Oct 2022
Last update posted
16 Sept 2025
Registered enrollment
3
Registry id
NCT05128773

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-000398-10

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.